MX2021008523A - Metodo para tratar una leucemia mieloide aguda. - Google Patents

Metodo para tratar una leucemia mieloide aguda.

Info

Publication number
MX2021008523A
MX2021008523A MX2021008523A MX2021008523A MX2021008523A MX 2021008523 A MX2021008523 A MX 2021008523A MX 2021008523 A MX2021008523 A MX 2021008523A MX 2021008523 A MX2021008523 A MX 2021008523A MX 2021008523 A MX2021008523 A MX 2021008523A
Authority
MX
Mexico
Prior art keywords
myeloid leukemia
acute myeloid
subject
treating
administering
Prior art date
Application number
MX2021008523A
Other languages
English (en)
Inventor
Marla L Weetall
Aniruddha Jayant Deshpande
Guerra Karina Ofelia Barbosa
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021008523A publication Critical patent/MX2021008523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aspecto descrito en la presente solicitud incluye un método para tratar leucemia mieloide aguda (AML) en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto inhibidor de polimerización de tubulina de molécula pequeña. De manera más particular, otro aspecto descrito en la presente solicitud incluye un método para tratar leucemia mieloide aguda en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva del compuesto inhibidor de polimerización de tubulina de molécula pequeña descrito en la presente solicitud en combinación con un agente quimioterapéutico.
MX2021008523A 2019-01-15 2020-01-15 Metodo para tratar una leucemia mieloide aguda. MX2021008523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962792502P 2019-01-15 2019-01-15
PCT/US2020/013645 WO2020150326A1 (en) 2019-01-15 2020-01-15 Method for treating an acute myeloid leukemia

Publications (1)

Publication Number Publication Date
MX2021008523A true MX2021008523A (es) 2021-11-12

Family

ID=69630611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008523A MX2021008523A (es) 2019-01-15 2020-01-15 Metodo para tratar una leucemia mieloide aguda.

Country Status (10)

Country Link
US (1) US20220096473A1 (es)
EP (1) EP3911418A1 (es)
JP (1) JP7428717B2 (es)
CN (1) CN113784757A (es)
AU (1) AU2020209767A1 (es)
BR (1) BR112021013913A2 (es)
CA (1) CA3126163A1 (es)
IL (1) IL284817A (es)
MX (1) MX2021008523A (es)
WO (1) WO2020150326A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG184755A1 (en) 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8524467B2 (en) * 2006-01-20 2013-09-03 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2008326251B2 (en) * 2007-11-21 2014-03-06 Mateon Therapeutics, Inc. Method for treating hematopoietic neoplasms
MX2020005345A (es) * 2009-05-27 2022-07-18 Ptc Therapeutics Inc Un método para inhibir o reducir una infección viral por coronavirus.
WO2014081906A2 (en) 2012-11-21 2014-05-30 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
JP2015212242A (ja) * 2014-05-02 2015-11-26 国立研究開発法人国立がん研究センター 白血病治療剤、白血病細胞増殖阻害剤、造血幹細胞移植前処置剤及び効果判定方法
WO2016113187A1 (en) * 2015-01-13 2016-07-21 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating leukemias
RU2759963C2 (ru) * 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака

Also Published As

Publication number Publication date
EP3911418A1 (en) 2021-11-24
JP7428717B2 (ja) 2024-02-06
IL284817A (en) 2021-08-31
CN113784757A (zh) 2021-12-10
BR112021013913A2 (pt) 2021-09-21
CA3126163A1 (en) 2020-07-23
JP2022518018A (ja) 2022-03-11
WO2020150326A1 (en) 2020-07-23
WO2020150326A8 (en) 2021-08-05
US20220096473A1 (en) 2022-03-31
AU2020209767A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
ZA202110357B (en) Inhibitor containing bicyclic derivative, preparation method therefor and use thereof
SG11202105197UA (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
EP3991733A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTICS
MX2022013081A (es) Compuestos para el tratamiento de sars.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2022001004A (es) Inhibidores de enzimas.
ECSP19083967A (es) Compuestos antitumorales
MX2022000944A (es) Combinaciones, mezclas y composiciones fungicidas y usos de las mismas.
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2021008523A (es) Metodo para tratar una leucemia mieloide aguda.
WO2020055544A3 (en) Method for treating pancreatic cancer
WO2021061874A3 (en) Methods and compositions for treating acute myeloid leukemia
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
MX2022000782A (es) Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2021011688A (es) Combinaciones utiles en un metodo para tratar sarcoma.
MX2021010398A (es) Metodo para tratar un mieloma multiple.
MX2022007974A (es) Metodos de tratamiento del cancer con anticuerpos anti-cd70 no fucosilados.
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi